Tay-Sachs disease results from biallelic pathogenic variants in HEXA (chromosome 15), encoding the alpha-subunit of beta-hexosaminidase A. ClinGen has classified the HEXA–Tay-Sachs disease relationship as DEFINITIVE. The condition follows autosomal recessive inheritance. The molecular mechanism involves failure to degrade GM2 ganglioside: without well-functioning HEX A, GM2 ganglioside accumulates in neuronal lysosomes, causing progressive cell dysfunction and death. GeneReviews genotype-phenotype analysis demonstrates an inverse correlation between residual HEX A enzyme activity and disease severity. Homozygosity or compound heterozygosity for null alleles results in complete enzyme absence and the severe infantile phenotype; null/missense compound heterozygosity yields intermediate residual activity and subacute juvenile presentations; two missense alleles with partial residual activity are associated with the late-onset phenotype.

Diagnostic evaluation for HEXA disorders is grounded in the level of residual beta-hexosaminidase A enzyme activity, as described in GeneReviews. Diagnostic methods documented in the packet include hexosaminidase A enzyme assay (using serum or leukocytes) and HEXA gene sequencing. Prenatal diagnosis is documented as available. Population-based carrier screening—particularly in Ashkenazi Jewish communities where carrier frequency is approximately 1 in 30—is listed as a diagnostic method in the packet. GeneReviews describes the diagnostic evaluation as encompassing HEX A enzyme activity testing, which provides the primary biochemical basis for classification across the disease continuum, alongside molecular confirmation via HEXA variant analysis. The condition is not listed on the HHS Recommended Uniform Screening Panel (RUSP) as a core newborn screening target.

GeneReviews describes treatment for acute infantile Tay-Sachs disease as supportive, directed at providing adequate nutrition and hydration, managing infectious disease, protecting the airway, and controlling seizures. For subacute juvenile and late-onset forms, GeneReviews documents management directed at maximizing function through physiatry and physical, occupational, and speech therapy services, with aids for activities of daily living. Foundational therapies documented in the packet include supportive care and symptom management, nutritional support and feeding assistance, seizure management with antiepileptic medications, physical therapy, and palliative care. No drugs with active FDA-approved market status for Tay-Sachs disease are documented in this packet. Multiple agents hold FDA orphan drug designation for Tay-Sachs or GM2 gangliosidoses—including Nizubaglustat (Azafaros B.V.), pyrimethamine (ExSAR Corporation), N-acetyl-glucosamine thiazoline (ExSAR Corporation), Gemfibrozil (Polaryx Therapeutics), and an AAV-based rAAV2/1 gene therapy vector—all with DESIGNATED status and without FDA approval for this indication.

GeneReviews describes infantile Tay-Sachs disease as uniformly fatal in early childhood, with most affected individuals entering a vegetative state and dying before age five years. The juvenile/subacute form carries a more variable prognosis with slower neurologic deterioration; life expectancy is reduced but extends into adolescence or early adulthood. The adult/late-onset form is associated with a longer and more variable course; GeneReviews notes that case reports document a wide spectrum of severity in this subtype, complicating prognostic generalization. GeneReviews acknowledges a paucity of prospective natural history studies delineating progression across disease subtypes over time, which limits the precision of available prognosis data.

Active clinical investigations for GM2 gangliosidosis (including Tay-Sachs disease) documented in this packet include: NCT07054515, a Phase 3 study of oral Nizubaglustat (AZ-3102) in late-infantile and juvenile GM2 gangliosidosis or Niemann-Pick Type C, sponsored by Azafaros B.V. (recruiting; estimated completion June 2028); NCT07399704, a Phase 2 study of Nizubaglustat in GM2 gangliosidosis, also by Azafaros (recruiting; estimated completion August 2030); NCT07445490, a translational ex vivo gene therapy study for GM2 gangliosidosis, sponsored by Assistance Publique–Hôpitaux de Paris (not yet recruiting; start estimated May 2026); and NCT00668187, a natural history study of the gangliosidoses (recruiting). GeneReviews documents additional ongoing investigation into N-acetyl-L-leucine (Phase 2 for GM2 gangliosidosis) and a multicenter venglustat pharmacodynamics study.